Table-II.
Comparison of characteristics between Groups I and II.
| Group I (77 patients) | Group II (23 patients) | P | |
|---|---|---|---|
| Age | 49.68±10.02 | 42.39±9.57 | 0.003 |
| Weight (kg) | 60.61±8.42 | 54.5±5.97 | 0.002 |
| Dose fraction (Gy) | 1.85±0.04 | 1.98±0.07 | 0.000 |
| Pelvic LN metastasis | 21.70% | 18.20% | 1.000 |
| Prior chemotherapy | 44.20% | 56.50% | 0.297 |
| Concurrent chemotherapy | 14.30% | 17.40% | 0.743 |
| Total chemotherapy | 49.40% | 60.90% | 0.332 |
| Block | 71.40% | 0.00% | |
| Hypertension | 16.00% | 0.00% | 0.063 |
| Diabetes | 3.90% | 0.00% | 1.000 |
| Transfusion (during surgery) | 32.47% | 0.00% | |
| V5IL | 757.55±97.56 | 875.92±104.96 | .000 |
| V10IL | 724.22±95.09 | 828.89±96.15 | .000 |
| V15IL | 704.3±93.57 | 777.84±91.96 | .003 |
| V20IL | 687.33±92.69 | 674.39±83.1 | .575 |
| V25IL | 671.77±91.86 | 554.8±79.71 | .000 |
| V30IL | 656.01±91.19 | 423.21±71.92 | .000 |
| V35IL | 638.43±90.74 | 299.52±65.86 | .000 |
| V40IL | 611±90.29 | 195±55.03 | .000 |
| V5LA | 342.99±55.6 | 329.76±42.85 | .494 |
| V10LA | 335.63±55.06 | 318.35±41.7 | .296 |
| V15LA | 331.06±54.45 | 309.8±41.28 | .170 |
| V20LA | 327.24±53.99 | 295.2±40.72 | .021 |
| V25LA | 323.98±53.68 | 262.71±44.92 | .000 |
| V30LA | 320.8±53.46 | 213.92±46.7 | .000 |
| V35LA | 317.37±53.41 | 156.91±39.66 | .000 |
| V40LA | 312.45±53.28 | 106.95±32.32 | .000 |
LN:lymph nodes; V5-V40:dose-volume histogram (DVH) calculated from 5 to 40 Gy at 5-Gy intervals;
IL:combination of ilium, ischium and pubis;
LA:lumbar vertebrae and sacrum.
The data are means ± standard deviation.